MCID: ADL042
MIFTS: 14

Adult Malignant Schwannoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Adult Malignant Schwannoma

MalaCards integrated aliases for Adult Malignant Schwannoma:

Name: Adult Malignant Schwannoma 12 15
Adult Neurofibrosarcoma 73
Adult Mpnst 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8369
NCIt 50 C7814
UMLS 73 C0278622

Summaries for Adult Malignant Schwannoma

MalaCards based summary : Adult Malignant Schwannoma, is also known as adult neurofibrosarcoma. An important gene associated with Adult Malignant Schwannoma is NF1 (Neurofibromin 1). The drugs Doxorubicin and Dacarbazine have been mentioned in the context of this disorder. Affiliated tissues include lung and bone.

Related Diseases for Adult Malignant Schwannoma

Symptoms & Phenotypes for Adult Malignant Schwannoma

Drugs & Therapeutics for Adult Malignant Schwannoma

Drugs for Adult Malignant Schwannoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
4
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
5
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
8
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
9
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
10
Epirubicin Approved Phase 3 56420-45-2 41867
11
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 6055-19-2, 50-18-0 2907
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
13 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
14 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
15 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
16 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
17 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
18 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
19 Immunologic Factors Phase 3,Phase 2,Phase 1
20 Anti-Infective Agents Phase 3,Phase 2,Phase 1
21
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
22 Etoposide phosphate Phase 3,Phase 2
23 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
24 Imatinib Mesylate Phase 2, Phase 3,Phase 1 220127-57-1 123596
25 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1
26 Antiviral Agents Phase 3,Phase 2,Phase 1
27 Antimitotic Agents Phase 3,Phase 2,Phase 1
28 Antimetabolites Phase 3,Phase 2,Phase 1
29 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
30
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
31
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
32
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
33
Bevacizumab Approved, Investigational Phase 2 216974-75-3
34
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
35
Xylometazoline Approved, Investigational Phase 1, Phase 2 526-36-3 5709
36
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
37
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
38
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
39
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
40
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
41
Pembrolizumab Approved Phase 2 1374853-91-4
42
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 445643 439492
43
Mesna Approved, Investigational Phase 2,Not Applicable 3375-50-6 598
44
Nivolumab Approved Phase 2 946414-94-4
45 Olaratumab Approved, Investigational Phase 2 1024603-93-7
46
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
47
Adenosine Approved, Investigational Phase 2 58-61-7 60961
48
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
50
Serine Approved, Nutraceutical Phase 2 56-45-1 5951

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
5 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
6 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
7 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
9 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
10 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Suspended NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
11 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
12 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
13 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Unknown status NCT01661283 Phase 2 everolimus;bevacizumab
14 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
15 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
16 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
17 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Completed NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
18 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
19 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
20 Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
21 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
22 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
23 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
24 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
25 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
26 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
27 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
28 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
29 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
30 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
31 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
32 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
33 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
34 MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 Completed NCT02096471 Phase 2 PD-0325901
35 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2 Pembrolizumab
36 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
37 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2 Tazemetostat
38 Hypofractionated Radiotherapy With Sequential Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
39 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
40 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
41 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
42 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
43 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
44 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Active, not recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
45 SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Not yet recruiting NCT03433183 Phase 2 Selumetinib;Sirolimus
46 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
47 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2
48 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Withdrawn NCT02986919 Phase 2 CPI-0610
49 Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients Completed NCT01169584 Phase 1 Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
50 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride

Search NIH Clinical Center for Adult Malignant Schwannoma

Genetic Tests for Adult Malignant Schwannoma

Anatomical Context for Adult Malignant Schwannoma

MalaCards organs/tissues related to Adult Malignant Schwannoma:

41
Lung, Bone

Publications for Adult Malignant Schwannoma

Variations for Adult Malignant Schwannoma

Expression for Adult Malignant Schwannoma

Search GEO for disease gene expression data for Adult Malignant Schwannoma.

Pathways for Adult Malignant Schwannoma

GO Terms for Adult Malignant Schwannoma

Sources for Adult Malignant Schwannoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....